l. amazonensis

PK 11195 (RP 52028) is a TSPO ligand for neuroimaging that exhibits significant protection against CoCl2-induced alterations and can be used to study leishmaniasis.

Butyrolactone V is a fungal metabolite that has been found in A. terreus and has antiprotozoal, antioxidant, and anticancer activities.1,2,3 It is active against the P. falciparum strain K1 (IC50 = 7.9 μg/ml) and L. amazonensis promastigotes (IC50 = 23.7 μM).2,1 Butyrolactone V (227 and 454.1 μM) is also active against adult S. mansoni worms.1 It scavenges 2,2-diphenyl-1-picrylhydrazyl and ABTS radicals with IC50 values of 20.7 and 3.7 μM, respectively, in cell-free assays.3 Butyrolactone V also inhibits proliferation of MDA-MB-231 and MCF-7 breast cancer cells (IC50s = 22.2 and 31.9 μM, respectively).1

2,3-Dehydro-3,4-dihydro ivermectin, an ivermectin analog and anthelmintic, demonstrates efficacy against L. amazonensis promastigotes and amastigotes, with IC50 values of 13.8 µM and 3.6 µM, respectively, while maintaining a low cytotoxicity profile in macrophages (IC50 = 65.5 µM).

Solasonine exerts leishmanicidal activity against promastigote forms of L. amazonensis.

Antileishmanial agent-1 demonstrates activity against both L. amazonensis promastigotes (IC 50 = 15.52 μM) and intracellular amastigotes (IC 50 = 4.10 μM).

PT4 is a treatment agent for Cutaneous leishmaniasis (CL). PT4 decreases of mitochondrial membrane potential and increases reactive oxygen species production, therefore leads to parasite death. PT4 is effective against both species of Leishmania. The IC50 values of PT4 against L. amazonensis and L. braziliensis are 125.18 and 233.18 μM , respectively. PT4 also shows potent anti-inflammatory activity in vivo [1].